FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2897679657> ?p ?o ?g. }

• W2897679657 endingPage "19088" @default.
• W2897679657 startingPage "19081" @default.
• W2897679657 abstract "Cyclophellitol aziridines are potent irreversible inhibitors of retaining glycosidases and versatile intermediates in the synthesis of activity-based glycosidase probes (ABPs). Direct 3-amino-2-(trifluoromethyl)quinazolin-4(3H)-one-mediated aziridination of l-ido-configured cyclohexene has enabled the synthesis of new covalent inhibitors and ABPs of α-l-iduronidase, deficiency of which underlies the lysosomal storage disorder mucopolysaccharidosis type I (MPS I). The iduronidase ABPs react covalently and irreversibly in an activity-based manner with human recombinant α-l-iduronidase (rIDUA, Aldurazyme® ). The structures of IDUA when complexed with the inhibitors in a non-covalent transition state mimicking form and a covalent enzyme-bound form provide insights into its conformational itinerary. Inhibitors 1-3 adopt a half-chair conformation in solution (4 H3 and 3 H4 ), as predicted by DFT calculations, which is different from the conformation of the Michaelis complex observed by crystallographic studies. Consequently, 1-3 may need to overcome an energy barrier in order to switch from the 4 H3 conformation to the transition state (2, 5 B) binding conformation before reacting and adopting a covalent 5 S1 conformation. rIDUA can be labeled with fluorescent Cy5 ABP 2, which allows monitoring of the delivery of therapeutic recombinant enzyme to lysosomes, as is intended in enzyme replacement therapy for the treatment of MPS I patients." @default.
• W2897679657 created "2018-10-26" @default.
• W2897679657 creator A5000584872 @default.
• W2897679657 creator A5010419684 @default.
• W2897679657 creator A5013935159 @default.
• W2897679657 creator A5017608631 @default.
• W2897679657 creator A5035632542 @default.
• W2897679657 creator A5040113503 @default.
• W2897679657 creator A5046393533 @default.
• W2897679657 creator A5047508911 @default.
• W2897679657 creator A5047831492 @default.
• W2897679657 creator A5049530878 @default.
• W2897679657 creator A5056673744 @default.
• W2897679657 creator A5057071421 @default.
• W2897679657 creator A5071351774 @default.
• W2897679657 creator A5077833697 @default.
• W2897679657 creator A5087597856 @default.
• W2897679657 date "2018-11-26" @default.
• W2897679657 modified "2023-10-17" @default.
• W2897679657 title "New Irreversible α‐<scp>l</scp>‐Iduronidase Inhibitors and Activity‐Based Probes" @default.
• W2897679657 cites W1981826353 @default.
• W2897679657 cites W1987152474 @default.
• W2897679657 cites W1987561426 @default.
• W2897679657 cites W1990892818 @default.
• W2897679657 cites W2015761210 @default.
• W2897679657 cites W2024759694 @default.
• W2897679657 cites W2035849215 @default.
• W2897679657 cites W2073005760 @default.
• W2897679657 cites W2090407227 @default.
• W2897679657 cites W2091075510 @default.
• W2897679657 cites W2095855268 @default.
• W2897679657 cites W2098260269 @default.
• W2897679657 cites W2104002701 @default.
• W2897679657 cites W2110221737 @default.
• W2897679657 cites W2120901082 @default.
• W2897679657 cites W2122559203 @default.
• W2897679657 cites W2168421325 @default.
• W2897679657 cites W2334713176 @default.
• W2897679657 cites W2343346222 @default.
• W2897679657 cites W2415790124 @default.
• W2897679657 cites W2623393796 @default.
• W2897679657 cites W2735441941 @default.
• W2897679657 cites W2765600382 @default.
• W2897679657 cites W3140959531 @default.
• W2897679657 cites W4233399977 @default.
• W2897679657 cites W4251558066 @default.
• W2897679657 doi "https://doi.org/10.1002/chem.201804662" @default.
• W2897679657 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6343074" @default.
• W2897679657 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30307091" @default.
• W2897679657 hasPublicationYear "2018" @default.
• W2897679657 type Work @default.
• W2897679657 sameAs 2897679657 @default.
• W2897679657 citedByCount "8" @default.
• W2897679657 countsByYear W28976796572019 @default.
• W2897679657 countsByYear W28976796572020 @default.
• W2897679657 countsByYear W28976796572021 @default.
• W2897679657 countsByYear W28976796572022 @default.
• W2897679657 countsByYear W28976796572023 @default.
• W2897679657 crossrefType "journal-article" @default.
• W2897679657 hasAuthorship W2897679657A5000584872 @default.
• W2897679657 hasAuthorship W2897679657A5010419684 @default.
• W2897679657 hasAuthorship W2897679657A5013935159 @default.
• W2897679657 hasAuthorship W2897679657A5017608631 @default.
• W2897679657 hasAuthorship W2897679657A5035632542 @default.
• W2897679657 hasAuthorship W2897679657A5040113503 @default.
• W2897679657 hasAuthorship W2897679657A5046393533 @default.
• W2897679657 hasAuthorship W2897679657A5047508911 @default.
• W2897679657 hasAuthorship W2897679657A5047831492 @default.
• W2897679657 hasAuthorship W2897679657A5049530878 @default.
• W2897679657 hasAuthorship W2897679657A5056673744 @default.
• W2897679657 hasAuthorship W2897679657A5057071421 @default.
• W2897679657 hasAuthorship W2897679657A5071351774 @default.
• W2897679657 hasAuthorship W2897679657A5077833697 @default.
• W2897679657 hasAuthorship W2897679657A5087597856 @default.
• W2897679657 hasBestOaLocation W28976796571 @default.
• W2897679657 hasConcept C104317684 @default.
• W2897679657 hasConcept C178790620 @default.
• W2897679657 hasConcept C180577832 @default.
• W2897679657 hasConcept C181199279 @default.
• W2897679657 hasConcept C185592680 @default.
• W2897679657 hasConcept C40767141 @default.
• W2897679657 hasConcept C55493867 @default.
• W2897679657 hasConcept C71240020 @default.
• W2897679657 hasConceptScore W2897679657C104317684 @default.
• W2897679657 hasConceptScore W2897679657C178790620 @default.
• W2897679657 hasConceptScore W2897679657C180577832 @default.
• W2897679657 hasConceptScore W2897679657C181199279 @default.
• W2897679657 hasConceptScore W2897679657C185592680 @default.
• W2897679657 hasConceptScore W2897679657C40767141 @default.
• W2897679657 hasConceptScore W2897679657C55493867 @default.
• W2897679657 hasConceptScore W2897679657C71240020 @default.
• W2897679657 hasFunder F4320307772 @default.
• W2897679657 hasFunder F4320338335 @default.
• W2897679657 hasIssue "71" @default.
• W2897679657 hasLocation W28976796571 @default.
• W2897679657 hasLocation W28976796572 @default.
• W2897679657 hasLocation W28976796573 @default.
• W2897679657 hasLocation W28976796574 @default.

• next